DelveInsight’s “Systemic Mastocytosis Market Insights” report delivers an in-depth understanding of the Systemic mastocytosis, historical & forecasted epidemiology, as well as the Systemic Mastocytosis Market Trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) for the study period 2019-2032.

 

Systemic Mastocytosis Overview      

 Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. It is typically diagnosed in adults. Systemic Mastocytosis (SM) is a rare myeloproliferative neoplasm (MPN) that is characterized by a clonal proliferation of mast cells (MCs). The symptoms and clinical presentation of SM are the result of both MC proliferation as well as activation and degranulation, causing hyperactive and over-exaggerated hypersensitivity responses, as well as organ infiltration by pathogenic.

 

Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-market

 

Systemic Mastocytosis Epidemiology Insights

Mastocytosis is a rare disorder, and its true incidence rates are unknown. One research study estimates that 1 in 10,000 people in the United States have this disease. Mastocytosis generally affects males and females equally. The disease can begin during childhood or adulthood (American Society of Clinical Oncology, 2021).

 

Some of the key highlights of the Systemic Mastocytosis Market Report

• In adults the presence of KIT D816V mutation is found in > 80% of cases, while in children, KIT mutations are found in > 75% of skin biopsies, however only 25% of these are D816V mutations.
• Systemic mastocytosis usually manifests after 2nd decade of life and peaks during the fifth and sixth decades.
• In a study by Italian Mastocytosis Registry, six hundred patients diagnosed with mastocytosis between 1974 and 2014. Among adults (n = 401); 156 (38.9%) patients were diagnosed with systemic mastocytosis (Merante et al., 2018).           
• In a study of 460 patients diagnosed with SM according to WHO 2008 criteria. SM subtypes were: ISM 89.1%, of which 54.9% were ISM with skin lesions (ISMs+), 40.2% ISM without skin lesions (ISMs-) and 4.9% SSM; ASM 6.1%; SM-AHNMD 4.6%; MCL 0.2% (Pieri et al., 2016).

 

Systemic Mastocytosis Epidemiology Segmentation in the 7MM (2019-2032)

• Total Systemic Mastocytosis Prevalent Cases
• Systemic Mastocytosis Age-specific Cases
• Systemic Mastocytosis Type-specific Cases
• Systemic Mastocytosis Mutation-specific Cases

 

Systemic Mastocytosis Types

The subtypes of SM include indolent SM (ISM), smoldering SM (SSM), aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL). Survival can range from normal in the case of ISM to months in MCL.

 

Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-market

 

Systemic Mastocytosis Symptoms

The signs and symptoms vary based on which parts of the body are affected but may include:

• Anemia and bleeding disorders

• Gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, and/or vomiting

• Itching, hives, and/or flushing of the skin

• Anaphylactoid reactions

• Enlarged liver (hepatomegaly), spleen (splenomegaly), and lymph nodes (lymphadenopathy)

 

Systemic Mastocytosis Causes

Most cases of systemic mastocytosis are caused by somatic mutations in the KIT gene. This gene encodes a protein that helps control many important cellular processes such as cell growth and division; survival; and movement. This protein is also important for the development of certain types of cells, including mast cells (immune cells that are important for the inflammatory response). Mutations in the KIT gene can leads to an overproduction of mast cells, which then accumulate in internal organs and lead to the symptoms of this condition.

 

Systemic Mastocytosis Diagnosis

A diagnosis of systemic mastocytosis (SM) is often suspected based on the presence of characteristic signs and symptoms. Additional testing can then be ordered to rule out other conditions with similar features; confirm the diagnosis; determine the type; and assess the severity. These tests may include: Bone marrow biopsy – the most useful test used to diagnose the condition.

• Blood studies – may show anemia, elevated histamine levels, thrombocytopenia, high white blood cell count (leukocytosis), low blood albumin levels (hypoalbuminemia), or high serum tryptase levels
• Imaging studies – may help to identify the extent and stage of the disease
• Biopsies of affected

 

Systemic Mastocytosis Treatment

The following medications may use to treat various symptoms associated with SM: Antihistamines to treat or prevent skin and gastrointestinal symptoms, Proton pump inhibitors to treat increased stomach acid, Epinephrine to treat anaphylaxis.

 

Systemic Mastocytosis Market Report Highlights

• In the coming years, the Systemic Mastocytosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Mastocytosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Systemic Mastocytosis. The launch of emerging therapies will significantly impact the Systemic Mastocytosis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Systemic Mastocytosis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

View Detailed Research Report Here @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-market

 

Table of content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Market Overview at a Glance

5. Disease Background and Overview

6. Patient Journey

7. Systemic Mastocytosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Mastocytosis Unmet Needs

10. Key Endpoints of Systemic Mastocytosis Treatment

11. Marketed Products

12. Emerging Therapies

13. Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Consult with our Business Expert @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/